IRIS
LAUDICELLA, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.586
NA - Nord America 3.534
AS - Asia 2.411
SA - Sud America 746
Continente sconosciuto - Info sul continente non disponibili 222
AF - Africa 81
OC - Oceania 3
Totale 11.583
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.396
RU - Federazione Russa 2.624
SG - Singapore 1.038
BR - Brasile 613
CN - Cina 520
IT - Italia 433
IE - Irlanda 422
SE - Svezia 390
HK - Hong Kong 295
DE - Germania 167
VN - Vietnam 155
FR - Francia 126
IN - India 102
PL - Polonia 87
GB - Regno Unito 84
CA - Canada 59
FI - Finlandia 51
AR - Argentina 50
BD - Bangladesh 43
MX - Messico 37
NL - Olanda 36
AT - Austria 31
JP - Giappone 31
ZA - Sudafrica 30
ID - Indonesia 29
TR - Turchia 29
BE - Belgio 27
ES - Italia 26
IQ - Iraq 26
LT - Lituania 23
VE - Venezuela 19
EC - Ecuador 15
PK - Pakistan 15
PE - Perù 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
MA - Marocco 13
UZ - Uzbekistan 13
AZ - Azerbaigian 11
CO - Colombia 11
IR - Iran 11
MY - Malesia 11
PH - Filippine 11
UA - Ucraina 11
IL - Israele 9
JM - Giamaica 9
PY - Paraguay 9
SA - Arabia Saudita 8
CL - Cile 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
GE - Georgia 6
CH - Svizzera 5
KE - Kenya 5
KW - Kuwait 5
PA - Panama 5
PT - Portogallo 5
UY - Uruguay 5
EG - Egitto 4
HN - Honduras 4
JO - Giordania 4
NO - Norvegia 4
NP - Nepal 4
AL - Albania 3
BG - Bulgaria 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
OM - Oman 3
PR - Porto Rico 3
SN - Senegal 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AU - Australia 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
DZ - Algeria 2
LU - Lussemburgo 2
NG - Nigeria 2
RO - Romania 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
CM - Camerun 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GY - Guiana 1
HR - Croazia 1
Totale 11.351
Salva come PNG Salva come JPEG
Città #
Moscow 797
Ashburn 607
Singapore 533
Dublin 420
Chandler 413
San Jose 300
Hong Kong 294
Nyköping 288
Dallas 264
Beijing 150
The Dalles 123
Los Angeles 116
Messina 114
Council Bluffs 111
Warsaw 78
Princeton 74
Munich 68
Medford 61
São Paulo 58
Ho Chi Minh City 54
Santa Clara 52
Lauterbourg 45
New York 45
Bremen 37
Des Moines 36
Redondo Beach 34
Buffalo 33
Rome 31
Hanoi 29
Hyderabad 28
Orem 27
Helsinki 26
Brussels 25
Frankfurt am Main 25
Nuremberg 23
Palermo 22
Montreal 21
Jacksonville 20
Stockholm 20
Tianjin 20
Denver 19
Johannesburg 19
Tokyo 19
Atlanta 18
Dearborn 17
Mumbai 17
Seattle 17
Turku 17
Amsterdam 16
Jakarta 16
Vienna 16
Milan 15
Chennai 14
Chicago 14
Columbus 14
Guangzhou 14
London 14
Porto Alegre 14
Boston 13
Brooklyn 13
Houston 13
Jinan 13
Rio de Janeiro 13
Boardman 12
Brasília 12
Curitiba 12
Phoenix 12
Poplar 12
Tashkent 12
Ben Arous 11
Campinas 11
Chengdu 11
Mexico City 11
Ann Arbor 10
Baku 10
Kameido 10
Lima 10
Nanjing 10
Pune 10
Toronto 10
Belo Horizonte 9
Bexley 9
Genoa 9
Istanbul 9
San Francisco 9
Shanghai 9
Shenzhen 9
Baghdad 8
Caracas 8
Dong Ket 8
Haiphong 8
Kuala Lumpur 8
Lappeenranta 8
Nanchang 8
Ankara 7
Betim 7
Cagliari 7
Guayaquil 7
Hangzhou 7
Philadelphia 7
Totale 6.224
Salva come PNG Salva come JPEG
Nome #
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 224
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 205
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 204
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 201
PRRT Retreatments: Renal Function Evaluation 200
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 199
Artificial intelligence in molecular imaging: from machine to deep learning 195
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 193
18F-FACBC in prostate cancer: A systematic review and meta-analysis 186
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 183
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 182
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 181
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 176
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 176
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 175
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 174
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 173
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 170
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 169
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 166
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma 164
Renal Function Evaluation in PRRT Retreatments 158
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 155
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 151
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas 150
PRRT retreatments: renal function evaluation 150
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 149
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 149
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 143
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 141
Correction to: 18F-FMISO PET imaging: insights over MRI in patients with glioma (Clinical and Translational Imaging, (2020), 8, 1, (3-10), 10.1007/s40336-019-00353-0) 137
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 134
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 132
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 130
Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation 127
Radiomics Analysis of Brain [18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis 126
68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement 122
Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination 122
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics 121
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 120
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 118
Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging 117
Emerging applications of imaging in glioma: focus on PET/MRI and radiomics 117
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome 116
PET/MR in neuro-oncology: is it ready for prime-time? 116
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature 115
[18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review 107
Sars-cov-2 persistence: data summary up to q2 2020 106
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 105
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 105
Molecular imaging of pancreatic neoplasms 104
From bench to bedside: highlights from the International Dialogue on Ovarian Cancer 101
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature 100
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature 98
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients 97
Malignant cutaneous melanoma: Updates in PET imaging 97
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study 97
[11C]Choline PET/CT in a Patient with Prostate Cancer Biochemical Recurrence Showing Two Suspicious Findings in the Breast and Liver 96
Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers 96
A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors 93
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics 91
[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond 91
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI 89
Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals 84
Prognostic insights of molecular imaging in cardiac sarcoidosis 84
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging 84
The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI 83
A Review of Advances in Molecular Imaging of Rheumatoid Arthritis: From In Vitro to Clinic Applications Using Radiolabeled Targeting Vectors with Technetium-99m 82
Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer 82
PET Imaging in Gliomas: Clinical Principles and Synergies with MRI 81
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 81
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 81
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 80
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 80
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study 79
[18F]PSMA‑1007 PET/CT‑based radiomics may help enhance the interpretation of bone focal uptakes in hormone‑sensitive prostate cancer patients 79
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 78
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT 72
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs) 69
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics 68
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 67
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork 66
Correction: PSMA‑positive prostatic volume prediction with deep learning based on T2‑weighted MRI 66
Reply to Perera Molligoda Arachchige AS [1] 65
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review 64
Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? 63
Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients 59
PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI 58
Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? 56
The role of PET radiomic features in prostate cancer: a systematic review 55
Unspecic bone uptakes in PSMA PET for prostate cancer: why do they matter? 53
[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature 53
Artificial Intelligence and Statistical Models for the Prediction of Radiotherapy Toxicity in Prostate Cancer: A Systematic Review 52
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding ­ [68Ga] Ga‑PSMA‑11 PET scans of primary prostate cancer 51
Monitoring of cardiac transthyretin amyloid load by [Tc-99m]DPD scintigraphy: is it the end of the semi-quantitative evaluation? 50
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer 49
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers 46
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years 46
Dose optimization in adult pet imaging: a balance between patient exposure and image quality. Literature review and future perspectives 37
Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review 32
Totale 11.320
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022458 0 30 4 22 31 13 27 34 6 54 35 202
2022/20231.384 119 196 70 107 88 140 17 89 482 16 36 24
2023/2024369 41 39 22 33 43 50 13 31 9 32 16 40
2024/20252.141 12 59 45 73 151 63 151 316 506 182 282 301
2025/20266.494 443 364 381 419 549 1.430 675 809 848 348 102 126
2026/2027327 156 171 0 0 0 0 0 0 0 0 0 0
Totale 11.583